

Reference:	FOI.1513.19
Subject:	Breast cancer treatments
Date of Request:	5 September 2019

Requested

1a. Does your trust treat advanced breast cancer?

1b. If none, where are your patients referred?

2. In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of:

- HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]
- HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]
- HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]
- HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] - Triple negative disease
- Not Known

3. In the past 3 months, how many breast cancer patients were treated with:

- Abemaciclib (Verzenios) + aromatase inhibitor *
- Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
- Alpelisib (Piqray) + Fulvestrant (Faslodex)
- Atezolizumab (Tecentriq)**
- Bevacizumab (Avastin)
- Eribulin (Halaven)
- Everolimus (Afinitor) + Exemestane
- Fulvestrant (Faslodex) as a single agent
- Gemcitabine + paclitaxel
- Lapatinib (Tyverb)
- Neratinib (Nerlynx)
- Olaparib (Lynparza)
- Palbociclib (Ibrance) + aromatase inhibitor*
- Pertuzumab (Perjeta) + trastuzumab + docetaxel
- Ribociclib (Kisqali) + aromatase inhibitor*
- Ribociclib (Kisqali) + Fulvestrant (Faslodex)
- Talazoparib (Talzenna)
- Trastuzumab + paclitaxel
- Trastuzumab as a single agent
- Trastuzumab emtansine (Kadcyla)
- Other active systemic anti-cancer therapy **

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested as it is estimated that the cost of answering your request would exceed the “appropriate level” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. The “appropriate level” represents the estimated cost of one person spending 18 hours or (2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The ChemoCare team, who hold a central record of cancer treatments, is based within Swansea Bay University Health Board (SBUHB). In order to provide you with the information requested, the UHB would be required to conduct a manual trawl of all cancer patients’ medical records to establish the type of cancer diagnosed and therapies used to treat the patients. It is estimated that conducting this search would take longer than the 18 hour ‘appropriate limit’ as stated within the Act.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000, which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the *appropriate limit*.

Under section 16 of the Freedom of Information Act, the UHB has an obligation to provide advice and assistance.

We would therefore recommend that you redirect your request to the Freedom of Information Team in SBUHB who may be able to help you with your enquiry: -

FOIA.Requests@wales.nhs.uk or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.